Targeted therapies in digestive oncology;Les thérapies ciblées dans la cancérologie digestive

Pathologie Biologie

Volumn 60, Issue 4, 2012, Pages 264-268

  Boutayeb, S ^a   Bensouda, Y ^a   Fadoulkhair, Z ^a   Bakkraoui, K ^a   Bachouchi, M ^b   Errihani, H ^a  

^a IBN SINA HOSPITAL   (Morocco)

^b Clinique Al Azhar   (Morocco)

Author keywords

Gastrointestinal cancers; Indication; Targeted therapies

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER;

ARTICLE; COLON CANCER; DIGESTIVE SYSTEM CANCER; DRUG INDICATION; DRUG SAFETY; ENDOCRINE TUMOR; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MOLECULARLY TARGETED THERAPY; PANCREAS CANCER; STOMACH CANCER;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS;

EID: 84864777581     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2012.05.013     Document Type: Article

References (29)

1. Christoffersen T. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. Eur J Pharmacol 2009, 625:6-22.
2. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
3. Kabbinavar F.F., Schulz J., McCleod M., Patel T., Hamm J.T., Hecht R., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705.
4. Saltz L.B., Clarke S., Díaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
5. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 2007, 25:1539-1544.
6. Allegra C.J., Yothers G., O'Connell M.J., Sharif S., Petrelli N.J., Colangelo L.H., et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011, 29:11-16.
7. Marshal J.L. Adjuvant therapy for Stage II and III colon cancer: consensus report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res 2007, 1:146-154.
8. Van Cutsem E., Tabernero J., Lakomy R. Intravenous aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational Phase III trial (EFC10262-VELOUR). Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
9. Sobrero A.F., Maurel J., Fehrenbacher L., Scheithauer W., Abubakr Y.A., Lutz M.P., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropirimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2311-2319.
10. Van Cutsem E, Lang I, Folprecht G, Nowacki M, Barone C, Shchepotin I, et al. Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. J Clin Oncol 2010; ASCO Proceeding, abstract 3570.
11. Van Cutsem E, Bokemeyer C, Heeger S, Sartorius U, Rougier P, Kohneet C, et al. Outcome according to metastatic site in patients with KRAS wild-type tumors: analysis from the CRYSTAL and OPUS studies. Gastrointestinal Cancers Symposium January 2011; abstract 472.
12. Bokemeyer C., Bondarenko I., Hartmann J.T., de Braud F., Schuch G., Zubel A., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011, 22:1535-1546.
13. Goldberg RM, Sargent DJ, Thibodeau SN, Mahoney MR, Shields AF, Chan E, et al. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 2010; ASCO Proceeding, abstract 3508.
14. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
15. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
16. Douillard J.Y., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28:4697-4705.
17. Peters M., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., et al. Randomised phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28:4706-4713.
18. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
19. Ohtsu A., Shah M.A., Van Cutsem E., Rha S.Y., Sawaki A., Park S.R., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011, 29:3968-3976.
20. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
21. Verweij J., Van Oosterom A., Blay J.Y., Judson I., Rodenhuis S., van der Graaf W., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003, 39:2006-2011.
22. The Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J Clin Oncol 2010, 28:1247-1253.
23. Dematteo R.P., Ballman K.V., Antonescu C.R., Maki R.G., Pisters P.W., Demetri G.D., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104.
24. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
25. George S., Blay J.Y., Casali P.G., Le Cesne A., Stephenson P., Deprimo S.E., et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009, 45:1959-1968.
26. Rimassa L., Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 2009, 9:739-745.
27. Van Cutsem E., Vervenne W.L., Bennouna J., Humblet Y., Gill S., Van Laethem J.L., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009, 27:2231-2237.
28. Rivera F., López-Tarruella S., Vega-Villegas M.E., Salcedo M. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 2009, 35:335-339.
29. Gao F, Visvardis EE, Sita-Lumsden A, Waxman J. Advances in the treatment of pancreatic neuroendocrine tumours. QJM 2012 [Epub ahead of print].